Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors

Assay and Drug Development Technologies

Volumn 9, Issue 5, 2011, Pages 503-513

  Cho, Goang Won ^a   Noh, Min Young ^a   Kang, Byung Yong ^a   Ku, Il Whea ^b   Park, Jiseon ^b   Hong, Yoon Ho ^c   Kim, Myung Hwa ^b   Kim, Seung Hyun ^a  

^a Hanyang University   (South Korea)

^b Jeil Pharmaceutical Co Ltd   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AMYLOID BETA PROTEIN; BROXURIDINE; COMPLEMENTARY DNA; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; NERVE GROWTH FACTOR; TAU PROTEIN;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION;

ALZHEIMER DISEASE; AMINOPHENOLS; ANIMALS; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; MALEIMIDES; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; PC12 CELLS; PHOSPHORYLATION; PLASMIDS; PYRIDINES; PYRIMIDINES; RATS; TAU PROTEINS;

EID: 80053346018     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2010.0343     Document Type: Article

References (37)

1. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980;107:519-527.
2. Cohen P, Goedert M: GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487.
3. Chin PC, Majdzadeh N, D'Mello SR: Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 2005;137:193-201.
4. Hooper C, Killick R, Lovestone S: The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008;104:1433-1439.
5. Hernandez F, Barreda EG, Fuster-Matanzo A, Goni-Oliver P, Lucas JJ, Avila J: The role of GSK3 in Alzheimer disease. Brain Res Bull 2009;80:248-250.
6. Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/ factor A. EMBO J 1990;9:2431-2438.
7. Cohen P, Frame S: The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-776.
8. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K: Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett 1996;203:33-36.
9. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, Wang Q, Xu H, Wang JZ: Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 2006;98:1167-1175.
10. Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH: Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem 2009;108:1116-1125.
11. Busciglio J, Lorenzo A, Yeh J, Yankner BA: Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995;14:879-888.
12. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K: Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 1993;90:7789-7793.
13. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, Radesater AC, Jerning E, Markgren PO, Borgegard T, Nylof M, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J: Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45945.
14. Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, Amitai G, Inestrosa NC: The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis 2005;18:176-183.
15. Panza F, Solfrizzi V, Frisardi V, Imbimbo BP, Capurso C, D'lntrono A, Colacicco AM, Seripa D, Vendemiale G, Capurso A, Pilotto A: Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: Drugs targeting beta-amyloid and tau protein. Aging Clin Exp Res 2009;21:386-406.
16. Alvarez G, Munoz-Montano JR, Satrustegui J, Avila J, Bogonez E, Diaz-Nido J: Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 1999;453:260-264.
17. Fu ZQ, Yang Y, Song J, Jiang Q, Liu ZC, Wang Q, Zhu LQ, Qang JZ, Tian Q: LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK- 3b in vivo and in vitro. J Alzheimers Dis 2010;21:1107-1117.
18. SerenóL, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, AgullóJM, Pérez M, Avila J, Guardia-Laguarta C, Clarimón J, LleóA, Gómez-Isla T: A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009;35:359-367.
19. Biernat J, Mandelkow EM: The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell 1999;10:727-740.
20. Cho JH, Johnson GV: Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 2003;278:187-193.
21. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, Lee VM: Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999;24: 751-762.
22. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM, Trojanowski JQ, Jakes R, Crowther RA, Spillantini MG, Burki K, Goedert M: Axonopathy and amyotrophy in mice transgenic for human fourrepeat tau protein. Acta Neuropathol 2000;99:469-481.
23. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F: Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 1999;155:2153-2165.
24. Takei Y, Teng J, Harada A, Hirokawa N: Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol 2000;150:989-1000.
25. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek MP: Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 2001;114:1179-1187.
26. Johnson GV, Stoothoff WH: Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 2004;117:5721-5729.
27. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA: Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain. EMBO J 1989;8:393-399.
28. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-526.
29. Lee G, Neve RL, Kosik KS: The microtubule binding domain of tau protein. Neuron 1989;2:1615-1624.
30. Delobel P, Mailliot C, Hamdane M, Sambo AV, Begard S, Violleau A, Delacourte A, Buee L: Stable-tau overexpression in human neuroblastoma cells: An open door for explaining neuronal death in tauopathies. Ann NY Acad Sci 2003;1010:623-634.
31. Sergeant N, Wattez A, Delacourte A: Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively "exon 10" isoforms. J Neurochem 1999;72:1243-1249.
32. Hong M, Chen DC, Klein PS, Lee VM: Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 1997;272:25326-25332.
33. Abraha A, Ghoshal N, Gamblin TC, Cryns V, Berry RW, Kuret J, Binder LI: Cterminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 2000;113 (Pt 21): 3737-3745.
34. Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P: The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: Evidence that wortmannin blocks activation of the mitogenactivated protein kinase pathway in L6 cells between Ras and Raf. Biochem J 1994;303:21-26.
35. Koh SH, Song C, Noh MY, Kim HY, Lee KY, Lee YJ, Kim J, Kim SH, Kim HT: Inhibition of glycogen synthase kinase-3 reduces L-DOPA-induced neurotoxicity. Toxicology 2008;247:112-118.
36. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL: Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008;22:246-260.
37. Augustinack JC, Schneider A, Mandelkow E, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 2002;103:26-35.